GP
VRTX icon

GLG Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

GLG Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,029
Closed -$433K – 509
2016
Q2 		$433K Buy
+5,029
New +$435K 0.01% 366
2015
Q4 		– Sell
-23,767
Closed -$2.48M – 528
2015
Q3 		$2.48M Buy
+23,767
New +$3.05M 0.07% 264
2015
Q2 		– Sell
-5,200
Closed -$613K – 515
2015
Q1 		$613K Sell
5,200
-53,785
-91% -$6.44M 0.02% 325
2014
Q4 		$7.01M Buy
58,985
+31,176
+112% +$3.51M 0.2% 131
2014
Q3 		$3.12M Buy
27,809
+12,809
+85% +$1.22M 0.07% 260
2014
Q2 		$1.42M Buy
+15,000
New +$1.05M 0.03% 287

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GLG Partners's VRTX Position: Q3 2016 in Review

GLG Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 5,029 shares — an estimated $433K sold.

GLG Partners first reported a position in VRTX in Q2 2014 and held it in 6 quarters. The position peaked at $7.01M in Q4 2014. 491 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

  • GLG Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • GLG Partners sold 5,029 Vertex Pharmaceuticals shares in Q3 2016, an estimated $433K.
  • GLG Partners first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 6 quarters.
  • GLG Partners's Vertex Pharmaceuticals position peaked at $7.01M in Q4 2014.
  • 491 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on GLG Partners's 13F filing for Q3 2016, filed 14 Nov 2016.